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Thyroid fine-needle aspiration biopsy (FNA)-cytology is widely used for the preoperative characterisation of thyroid nodules but this
task is difficult for follicular lesions, which often remain undefined. We propose a strategy for improving the preoperative
characterisation of selected follicular thyroid proliferations, which is based on large needle aspiration biopsy (LNAB) and galectin-3
expression analysis. Eighty-five thyroid specimens were obtained by LNAB (20-gauge needles) from thyroid nodules with
indeterminate follicular FNA-cytology. Aspirated material was processed as a tissue microbiopsy to obtain cell blocks for both cyto/
histo-morphological evaluation and galectin-3 expression analysis, by using a purified monoclonal antibody to galectin-3 and a biotin-
free immunoperoxidase staining method. Preoperative diagnosis was compared to the final histology. LNAB and cell-block technique
allow a preliminary distinction between nodules with a homogeneous microfollicular/trabecular structure, as frequently observed in
tumours, and lesions with mixed normo–micro–macrofollicular architecture, as observed in goitre. Furthermore, LNAB provides
optimal substrates for galectin-3 expression analysis. Among 85 cases tested, 14 galectin-3-positive cases were discovered
preoperatively (11 thyroid cancers and three adenomas confirmed at the final histology), whereas galectin-3-negative cases were 71
(one carcinoma and 70 benign proliferations at the final histology). Sensitivity, specificity and diagnostic accuracy of this integrated
morphologic and phenotypic diagnostic approach were 91.6, 97.2 and 95.3%, respectively. In conclusion, LNAB plus galectin-3
expression analysis when applied preoperatively to selected thyroid nodules candidate to surgery can potentially reduce unnecessary
thyroid resections.
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Preoperative characterisation of thyroid nodules is a common
clinical problem. It has been estimated that about 4% of the
American population between the ages of 30 and 60 years has one
or more palpable thyroid nodules.
As the majority of these lesions are benign, their preoperative
evaluation should be as selective as possible in the recommenda-
tion for surgical removal.
Thyroid fine-needle aspiration biopsy (FNA) is a well-
established diagnostic technique, which, in the right hands, signifi-
cantly reduces the number of thyroid surgical resections (Kini,
1987; Hamburger et al, 1979, 1989; Gharib, 1994; Carpi et al, 1996;
Baloch et al, 1998; Khurana et al, 1999). Although FNA cytology of
microfollicular nodules shows in some series a relatively high
predictive value for the diagnosis of follicular neoplasms (Basu and
Jayaram, 1992; Gutman and Henry, 1998), this method has
important intrinsic limitations in distinguishing benign from
malignant follicular lesions. This task, in fact, requires the
unequivocal demonstration of capsular and/or vascular invasion,
which is possible only at postoperative histology (Rosai et al, 1992;
Bartolazzi, 2000). However, practice guidelines for the clinical
management of thyroid nodules suggest that an initial FNA is more
useful and cost-effective than other forms of diagnostic procedures
(Hamburger et al, 1989). Large studies from single specialised
Institutions reported a sensitivity and specificity higher than 90%
leading many clinicians to recommend thyroid FNA-cytology
as the initial diagnostic test in the evaluation of thyroid nodules.
Surprisingly, a large prospective cohort study indicates that
thyroid FNA-cytology was used as the initial diagnostic procedure
in about 53% of the cases (Hundahl et al, 2000). Furthermore, an
European survey on the clinical management of nodular thyroid
lesions showed that thyroid FNA-cytology was indicated as the
first diagnostic procedure by 41% of the responders, if they had to
choose only one diagnostic test, and by only 25% when more than
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sone test could be considered (Baldet et al, 1989). These data clearly
confirm that the clinician’s confidence in thyroid FNA-cytology is
still low. The fact mostly reflects the large variability of thyroid
FNA performance in not specialised Thyroid Hospitals and Cancer
Centres.
In Community Hospitals, in fact, thyroid FNA-cytology is likely
more affected by subjective evaluations, technical skills and bias of
interpretations. As a consequence, the prevalence of indeterminate
cytological reports indicating ‘follicular proliferations not other-
wise specified’ is quite high.
In this report, we investigate whether the use of large needle
aspiration biopsy (LNAB), mostly performed with 20-gauge
needles, from which tissue microbiopsies and cell blocks can be
prepared (Carpi et al, 1996, 1998, 2000), may improve the
preoperative evaluation of selected follicular thyroid nodules. In
addition, we wished to evaluate whether LNAB could provide
better substrates for galectin-3 expression analysis compared to
conventional FNA-cytology (Gasbarri et al, 2004).
The expression analysis of the b-galactosyl binding protein
galectin-3 has been recently proposed for clinical use with the aim
to improve the diagnostic performance of conventional FNA-
cytology in distinguishing, preoperatively, benign from malignant
thyroid lesions (Orlandi et al, 1998; Gasbarri et al, 1999; Inohara
et al, 1999; Bartolazzi, 2000; Bartolazzi et al, 2001). Galectin-3 is
undetectable in the cytoplasm of normal thyroid follicular cells,
but it is almost invariably expressed in malignant transformed
thyrocytes and in macrophages (Inohara et al, 1999; Bartolazzi
et al, 2001). The biological role of galectin-3 expression in
transformed thyrocytes is not completely understood. Interest-
ingly, nuclear expression of galectin-3 regulates gene transcription
and induces apoptosis. On the other hand, when galectin-3
accumulates in the cytoplasm of thyroid cells it blocks the
apoptotic programme and let the development of cancer (Yoshii
et al, 2001; Liu and Rabinovich, 2005). The diagnostic potential of
galectin-3 expression analysis in distinguishing benign from
malignant thyroid nodules has been recently evaluated in a large
International Multicentric Study (Bartolazzi et al, 2001). Galectin-3
test method seems to be a promising diagnostic tool for improving
the clinical management of patients bearing follicular thyroid
proliferations. However, its clinical application is still pending
(American Thyroid Association Consensus Guidelines for Thyroid
Testing, 2003; Cooper et al, 2006).
In this study, we focus on selected follicular thyroid nodules that
remained indeterminate at conventional FNA cytology. For these
lesions, it was not possible to analyse galectin-3 expression on
cytological preparations for scanty material and/or other technical
reasons.
The diagnostic performance of LNAB plus galectin-3 expression
analysis was tested on 85 follicular thyroid nodules candidate to
surgery and compared with postoperative histology.
MATERIALS AND METHODS
Patients
Two groups of patients with follicular thyroid nodules were
considered in this study.
All of them were referred to surgery because follicular lesions
remained undefined after conventional FNA-cytology. A retro-
spective group included 65 patients, 50 women and 15 men, mean
age 44 years. Forty-eight patients out of 65 were referred for
a single thyroid nodule, whereas 17 out of 65 showed multiple
thyroid nodules. The mean size of the single or dominant nodule
object of this study was 2.66cm (lesions ranging from 1 to 6cm).
Conventional FNA-cytology produced indeterminate reports,
namely ‘follicular proliferation not otherwise specified’ in 42 of
the instances, whereas presence of ‘follicular proliferations with
atypical cells’ was observed in 23 of the cases. The evaluation of
galectin-3 expression on FNA-material was not possible for
technical reasons (poor cellularity, cell blocks not available, etc.).
Large needle aspiration biopsy (mostly by using 20-gauge needles)
was performed preoperatively in all the instances and galectin-3
expression analysis was applied retrospectively on LNAB-derived
cell blocks.
In the prospective study, 20 patients bearing follicular thyroid
nodules were subjected to preoperative LNAB plus galectin-3
expression analysis. Sixteen out of 20 patients were women, mean
age 51 years. In 16 of the instances patients were referred for a
single thyroid nodule whereas multiple nodules were diagnosed in
four of the cases. The mean size of the single or dominant thyroid
nodule object of the study was 2.36cm (ranging from 1 to 4.3cm).
Conventional FNA-cytology resulted indeterminate in 17 out of 20
cases. Coexistence of atypical or suspicious thyroid cells was
observed in two of the instances, whereas oncocytic features were
detected in one case. All the patients underwent partial or total
thyroidectomy and the final histological diagnosis was performed
by two independent pathologists and considered as the gold
standard.
LNAB and galectin-3 test method (galectin-3 thyrotest)
LNAB procedures We adopted a simple and safe method of
LNAB, which employs usually 20-gauge needles and exceptionally,
in the largest nodules, 18-gauge needles introduced percutaneously
(Carpi et al, 1996, 2000). When inserted into the lesion, the needle
is rotated within the nodule so that its sharp end severs the tissue
fragments.
The technique that was first described in 1930 (Martin and Ellis,
1930) does not show consistent differences with respect to
conventional FNA-cytology (Hamburger et al, 1979; Carpi et al,
1996, 2000). Patients usually do not experience more discomfort,
pain or complications than with conventional FNA method (21–
25-gauge needles). Aspirated material and tissue fragments were
processed to obtain paraffin-embedded cell blocks.
Formalin-fixed and paraffin-embedded cell blocks were pro-
cessed to obtain seriate tissue sections for both morphologic
analysis and phenotypic studies.
The morphologic evaluation of LNAB specimens let a pre-
liminary distinction between nodules with a homogeneous
microfollicular–trabecular structure, which is suggestive of
tumour, from lesions with mixed normal–micro–macrofollicular
architecture, which more likely represents a hyperplasic condition
(goitre). Furthermore, the nuclear clearing, which represents an
important feature of papillary thyroid carcinoma, can be easily
appreciated in thyroid preparations from formalin-fixed and
paraffin-embedded cell blocks. This is particularly important for
the follicular variant of papillary carcinoma, which sometimes
remains indeterminate at conventional FNA-cytology.
Galectin-3 test-method A purified rat monoclonal antibody
(mAb) to galectin-3 (Mabtech, Nacka, Sweden) was used in
immunohistochemistry according to the manufacturer’s instruc-
tions. Briefly, antigen-retrieval microwave treatment of tissues
slides in 0.01moll
 1 citrate buffer pH 6.0 was applied as required.
To minimise the occurrence of false-positive results, a biotin-free
immunoperoxidase staining method was considered in this study.
This was obtained by using a horseradish-peroxidase-conjugated
(HRP-conjugated) rabbit anti-rat immunoglobulins as secondary
antibodies, in indirect immunoperoxidase assay (Dako, Glostrup,
Denmark). Purified rat mAb directed to galectin-3 was used at
a concentration range of 5–10mg/ml. After incubation with HRP-
conjugated secondary antiserum, the enzymatic activity was
visualised with 3,30-diamino-benzidine (Dako).
Positive cases were classified as þ/  when a heterogeneous
immunostaining was restricted to isolated follicular cells or small
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sclusters of cells, and þ when the majority of thyroid cells in
the follicular lesion showed galectin-3 expression. At least two
experienced pathologists performed the immunohistochemical
evaluation independently.
Statistical analysis
Sensitivity, specificity, positive (PPV) and negative (NPV)
predictive values, and diagnostic accuracy of the proposed
immunodiagnostic method were assessed as follows:
The final histology (after surgery) was considered as the gold
standard.
Sensitivity was defined on the basis of thyroid cancer immuno-
detection as: no. of carcinomas tested galectin-3 positive/total
number of thyroid cancers. Specificity was defined on the basis
of benign thyroid lesion immunodetection as: no. of benign
lesions tested galectin-3 negative/total number of benign lesions.
Frequency was assessed as: no. of thyroid cancers/total no. of
individuals in our study. Finally, the PPV and NPV were,
respectively, computed as: no. of carcinomas tested positive/total
no. of tested positive cases, and no. of benign lesions tested
negative/total no. of tested negative cases, respectively. Diagnostic
accuracy was calculated as (no. positiveþno. negative)/(true
positiveþfalse positiveþtrue negativeþfalse negative). STAT 6
statistical software was used to estimate the above reported
parameters. This study has been carried out according to the
ethical guidelines of the Declaration of Helsinki. Specific
authorisation was obtained from each enrolled patient.
RESULTS
Table 1 shows the comparative evaluation of LNAB plus galectin-3
expression analysis and the final histology in 85 follicular nodules
with indeterminate FNA-cytology.
Although LNAB procedures, as well as conventional FNA
cytology, fail to distinguish between benign and malignant
follicular lesions, the former provides a better sampling of the
lesion, with more aspirated material and improved architectural
view (Figure 1).
In fact, a careful morphologic evaluation of the collected LNAB
material let us a preliminary distinction of the follicular thyroid
nodules in two major groups: (a) follicular proliferations with
homogeneous microfollicular/solid or trabecular architecture,
which suggests a thyroid neoplasia, and (b) follicular lesions with
mixed micro–normal–macrofollicular structure, which more
likely suggests a nodular hyperplasia (thyroid goitre).
As reported in Table 1, nodules showing at LNAB a homo-
geneous microfollicular/solid architecture were observed in 39 out
of 85 instances (45.9%). In about 50% of these cases, the final
histology confirmed the presence of benign or malignant tumours:
13 adenomas (33.3% of the cases) and six carcinomas (15.4%).
Nodules with mixed follicular structure were detected in 45 out
of 85 cases tested (52.9%). Postoperative histology showed thyroid
hyperplasia in 34 of the instances (75.5% of the cases). In this
group of lesions, six (13.3%) adenomas were histologically
detected whereas thyroid malignancies, which were invariably
represented by follicular variant of papillary carcinomas, were
five (11.1%). The proportion of suspected neoplastic or hyper-
plasic nodules between the two groups of follicular proliferations,
as evaluated by preoperative LNAB, was statistically significant
(w
2¼4.36; P¼0.0244).
The immunophenotypic analysis of microfollicular/solid no-
dules evaluated on LNAB specimens, showed galectin-3 expression
in five out of 39 cases (Figure 2). All of them were finally diagnosed
as thyroid malignancies (Table 1). Postoperative histology
demonstrated, in fact, the presence of two follicular variants of
papillary carcinoma, a papillary carcinoma with solid/poorly
differentiated areas, a follicular carcinoma with oncocytic features
and one conventional follicular carcinoma. The latter showed a
heterogeneous expression of galectin-3, with several negative
neoplastic cells.
Among the 34 galectin-3-negative microfollicular/solid lesions,
13 were histologically classified as follicular adenomas (39.3%), 20
as nodular hyperplasias (58.8%) and one as follicular carcinoma.
The latter should be considered a true galectin-3-negative
carcinoma because the lack of expression of galectin-3 was
confirmed by immunohistochemistry after surgery.
On the other hand, among the 45 LNAB cases with mixed
follicular architecture, which were suspicious for benign thyroid
conditions, postoperative histology confirmed hyperplasia in 34 of
Table 1 Preoperative LNAB plus Galectin-3 expression analysis vs postoperative histology
Preoperative diagnosis Postoperative histology
LNAB Galectin-3 expression Cancer Adenoma Hyperplasia
Microfollicular/solid 39 (45.9%) Gal-3+ 5 5 0 0
Gal-3  34 1 13 (33.3%) 20 (59.3%)
Atypical cells 1 Gal-3+ 1 1 0 0
Gal-3  00 0 0
Follicular/mixed architecture 45 (52.9%) Gal-3+ 8 5 3
a 0
Gal-3  37 0 3 34 (75.5%)
Total 85 85 12 19 54
aTwo of these galectin-3-positive adenomas showed capsular impingement of neoplastic cells.
%¼percentage in Table 1 are referred to the total number of cases.
Figure 1 Comparative morphologic evaluation (FNA vs LNAB) of micro
follicular/solid thyroid nodule (panels A and B) and follicular nodule with
mixed architecture (panels C and D). Cell blocks/microhistology clearly
provide better morphologic details of the lesions (panels B and D).
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sthe cases (75.5%). Interestingly, all of them were invariably
galectin-3 negative. It is noteworthy that all of the five thyroid
carcinomas in this group were immunoreactive with the mAb to
galectin-3. Galectin-3 expression was also detected in three out
of six histologically confirmed follicular adenomas. Two of these
lesions were finally diagnosed as ‘follicular proliferations with
undefined malignant potential (UMP) (Rosai et al, 1992; Papotti
et al, 2005) because evidence of capsular impingement of the
neoplastic cells, without clear aspects of invasion, was histologi-
cally demonstrated after evaluation of multiple tissue sections.
In one instance, LNAB material showed galectin-3-positive
atypical cells. Also in this case the final histological report
confirmed the presence of a papillary carcinoma.
Sensitivity and specificity of this integrated diagnostic approach
were 91.6 and 97.2%, respectively. The PPV was 78.4% (492% if
galectin-3-positive follicular proliferations UMP are considered as
early transformed lesions or ‘thyroid cancer precursor lesions’)
(Bartolazzi et al, 2001; Papotti et al, 2005), whereas the NPV was
98.6%. Diagnostic accuracy assessed in this study was 95.3%, and
frequency 14.1.
DISCUSSION
FNA-cytology is widely used for the preoperative evaluation of
thyroid nodules, but its optimal diagnostic performance is
restricted to thyroid specialised hospitals and cancer centres.
However, it is well known that thyroid FNA-cytology has per se
important intrinsic limitations in distinguishing benign from
malignant follicular lesions (Kini, 1987; Rosai et al, 1992; Gharib,
1994). Even in ‘the right hands’ the rate of inadequate smears is
rarely lower than 10%, and up to 30% of FNA cytological reports
remain undefined (Kini, 1987; Rosai et al, 1992; Gharib, 1994).
For this reason, the characterisation of follicular thyroid nodules
is widely considered as the ‘grey zone of FNA-cytology’. Many
authors reported that high cellularity, nuclear features, scanty
colloid and presence of microfollicular structures are the principal
morphologic features to be considered for a better cytological
diagnosis of a follicular neoplasm (Rojeski and Gharib, 1985; Kini,
1987; Hamburger et al, 1989; Gharib, 1994; Baloch et al, 1998;
Gutman and Henry, 1998). Combination of high cellularity,
microfollicular/solid pattern and nuclear atypia are predictive of
a follicular neoplasm in the majority of the instances (Basu and
Jayaram, 1992; Solomon, 1993; Carpi et al, 2000) but these features
are not sufficient for distinguishing between benign and malignant
lesions (Mazzaferri, 1993; Greaves et al, 2000).
We and other laboratories have recently proposed the use of
galectin-3 expression analysis for the preoperative characterisation
of follicular thyroid nodules (Orlandi et al, 1998; Gasbarri et al,
1999; Inohara et al, 1999; Bartolazzi et al, 2001; Herrmann et al,
2002; Collet et al, 2005). Although many reports have been
published on this issue during the last decade (about 100 papers
are displayed in Pub Med since 1997) some authors experienced
conflicting results with the use of galectin-3 for improving
diagnosis of follicular thyroid proliferations (Martins et al,
2002; Niedziela et al, 2002; Feilchenfeldt et al, 2003; Jakubiak-
Wielganowicz et al, 2003; De-Leon-Mazariegos et al, 2004;
Mehrotra et al, 2004; Mills et al, 2005). However, some of these
reports show major methodological problems (Herrmann et al,
2002; Bartolazzi et al, 2003; Bartolazzi and Bussolati, 2006). The
use of reverse transcriptase (RT-PCR)–polymerase chain reaction
technique for evaluation of galectin-3 expression in thyroid
nodules, in fact, can produce false positive results because foamy
thyroid macrophages, endothelial cells and some activated
lymphocytes normally express galectin-3 (Bartolazzi et al, 2003).
Furthermore, the use of purified monoclonal antibodies to
galectin-3 in a biotin-free detection system is advisable in order
to reduce the occurrence of false-positive results. This may be
important when galectin-3 test method is used for the diagnostic
purpose (Herrmann et al, 2002; Bartolazzi et al, 2003; Bartolazzi
and Bussolati, 2006).
Although galectin-3 test method may be further optimised in
order to be widely used in the clinical practice on conventional
cytological preparations, the results of a large prospective multi-
centric study, which is running at national level, seems to confirm
its diagnostic value (work in preparation).
HBME1, CK19, CD26/DPPIV, TPO and c-met have also been
reported to be useful markers for improving the preoperative
characterisation of thyroid nodules (De Micco et al, 1994, 1999;
Ruco et al, 2001; Aratake et al, 2002; Rosai, 2003; Maruta et al,
2004; Mechanick, 2004; Weber et al, 2004; Papotti et al, 2005;
Prasad et al, 2005; Saggiorato et al, 2005; de Matos et al, 2005).
Among the aforementioned molecules, TPO is the largest
preoperatively investigated tumour marker with a high overall
accuracy (De Micco et al, 1994, 1999; Christensen et al, 2000;
Weber et al, 2004). However, for the majority of these molecules
the biological rationale of their preferential expression in thyroid
cancer is still missing.
Anyway it should be stressed that LNAB and cell-block
technique can eventually provide optimal substrates for compara-
tive immunohisto-cytochemistry (on seriate tissue sections)
directed to evaluate the expression of galectin-3 and other
potential markers of thyroid cancer. This analysis is almost
impossible to be performed on conventional cytological smears.
In this report, we show that LNAB plus galectin-3 determination
led to correctly identify almost all of the benign thyroid nodules
(97%), which were considered as suspicious following conven-
tional FNA cytology. If it is true that FNA-derived cellular
specimens are obtained and handled more easily and cheaply
than LNAB-derived small tissue fragments, it should be mentioned
that the occurrence of inadequate cytological specimens is higher
with FNA than with LNAB preparations obtained with 20-gauge
needle (Carpi et al, 1996, 1998). It has been recently reported that
about 23% of thyroid aspirates have a low cellularity and are not
suitable for cell-block preparation and galectin-3 immunostaining
(Mills et al, 2005). In our experience, LNAB performed with
20-gauge needle retrieves much more tissue than FNA to be processed
as paraffin-embedded cell block (Gasbarri et al, 2004). Most
important, LNAB-derived cell blocks remain available for repeti-
Figure 2 Galectin-3 thyrotest negative on follicular hyperplasia (panel
A). The inset shows endothelial cells and one foamy macrophage galectin-3
positive as internal controls. A microfollicular adenoma galectin-3 negative
(panel B). Solid/trabecular (panel C) and micro follicular (panel D) thyroid
malignancies, both of which are immunoreactive for galectin-3 (indirect
immunoperoxidase biotin-free).
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stion of the galectin-3 test as well as for testing of different markers
at any time.
Thyroid LNAB is safe as reported in series of thousands
consecutive examinations (Crile and Hawk, 1973; Hamburger et al,
1979; Carpi et al, 1996, 2000). One of us (A Carpi) performed more
than 3000 LNABs in the last decade with a few (about 10) minor
complications consisting in relatively large haematomas with
spontaneous resolution. However, the purpose of this method
is not for routine cyto/histological evaluation of thyroid nodules,
but it should be restricted to those selected lesions referred to
surgery because indeterminate at conventional FNA-cytology. In
our series, a preliminary distinction between neoplastic nodules
(benign or malignant) and hyperplasia (goitre) was possible on
morphological bases alone in more than 73% of the cases, by using
cell-block preparations conventionally stained with haematoxylin
and eosin (microhistology). When galectin-3 thyrotest was applied
on the same substrates, the diagnostic accuracy of the method
improved consistently up to 95%. Interestingly, among the 12
thyroid carcinomas detected at the final histology, only one did not
express galectin-3. However, this lesion, although indeterminate
at conventional FNA-cytology, was considered morphologically
suspicious for neoplasia, because a microfollicular structure
with clear nuclei was evident at LNAB microhistology (paraffin-
embedded and formalin-fixed tissue section). Most important,
none of the histologically confirmed hyperplasic conditions
(goitres) showed expression of galectin-3. Therefore, the NPV of
the proposed integrated diagnostic method is very high (497%)
when the galectin-3 test method is correctly applied (Bartolazzi
et al, 2001, 2003; Bartolazzi and Bussolati, 2006).
Regarding the detection of some galectin-3-positive follicular
adenomas, we previously reported that these lesions may likely
represent early follicular carcinomas, in which capsular and/or
vascular invasion cannot be demonstrated yet (Bartolazzi et al,
2001).
In this study, we detected three galectin-3-positive follicular
adenomas out of 19 tested.
We believe that surgical excision of these specific lesions may
be advisable and does not represent a real overtreatment. In fact,
the expression of galectin-3 in thyroid cells drives the block of
apoptosis, a biological feature that is not observed in normal cells
(Yoshii et al, 2001; Takenaka et al, 2003; Liu and Rabinovich,
2005).
In our series, the number of follicular cancers is limited for
evaluating galectin-3 diagnostic sensitivity for these specific
malignancies. However, data from us and other laboratories show
that galectin-3 test method works well also in follicular carcinomas
(Bartolazzi et al, 2001; Oestreicher-Kedem et al, 2004; Collet et al,
2005; Papotti et al, 2005; Saggiorato et al, 2005). By the practical
point of view, the incidence of well-differentiated follicular
carcinomas is low (less than 10% of the cases) and is markedly
reduced in countries without iodine deficiency. In fact, in many
series including excised nodules with indeterminate FNA cytology,
the follicular variant of papillary carcinoma is the most common
thyroid malignancy detected at histology (Hooft et al, 2004; Miller
et al, 2004; Carpi et al, 2005).
In conclusion, thyroid LNAB when integrated with galectin-3
expression analysis provides a potent and reliable diagnostic
tool for improving the clinical management of patients bearing
follicular thyroid nodules. The purpose of LNAB and galectin-3
expression analysis is not to replace conventional thyroid
FNA-cytology, which remains in our opinion, the most important
screening method for thyroid proliferations. The combined
diagnostic approach we propose should be applied in all the
instances in which FNA is inadequate for technical or logistic
reasons and galectin-3 thyrotest cannot be performed on FNA-
derived material. LNAB-derived cell blocks and galectin-3 test
method let a better preoperative selection of patients candidate to
surgery. A consistent reduction of hospitalisation and social costs
are expected when most of the unnecessary surgery for benign
thyroid nodules will be avoided.
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